On November 28th (Tue) to 30th (Thu), 2023, the delegates from PhIRDA (China Pharmaceutical Innovation and Research Development Association, 中国医药创新促进会) with 25 members in total, including Dr. Song Ruilin, Executive President, PhIRDA (宋瑞霖执行会长) as well as corporate executives of Luye Pharma (绿叶制药), Ascentage Pharma (亚盛医药), Kelun Pharma (科伦药业) and Henlius Biotech (复宏汉霖), came to Japan and visited pharmaceutical companies, the Japan Pharmaceutical Manufacturers Association (JPMA), the National Cancer Center (NCC), Science Park, etc. in Tokyo and Kanagawa.

As a supporter on the Japan side, Mr. Tetsuomi Takano, Editor-in-Chief, Drug R&D Expert as well as President and CEO, t2T Healthcare Inc., gave a lecture presentation titled “Japanese Pharmaceutical Companies’ Ideas on New Drug Development in Japan, China and Globally” as well as coordinated meetings with JPMA and NCC, and accompanied the delegates from PhIRDA for three days.

PhIRDA’s released article on their visit to Japan on their website (Chinese)
https://mp.weixin.qq.com/s/mxeMXkHEUv3r3fGdNJh7iQ